See the DrugPatentWatch profile for Ertapenem
Ertapenem is an injectable carbapenem-class antibiotic used to treat moderate to severe infections caused by susceptible bacteria. It is effective against a range of Gram-positive and Gram-negative bacteria, including many anaerobic organisms [1].
When does ertapenem's patent protection end?
The primary patents for ertapenem expired in 2017 [2]. This means that generic versions of ertapenem can now be legally manufactured and sold, potentially leading to lower prices.
What are the risks of using ertapenem?
Like all antibiotics, ertapenem can cause side effects. Common adverse reactions include diarrhea, nausea, headache, and infusion site reactions [3]. More serious, though less common, risks include Clostridioides difficile-associated diarrhea, seizures, and hypersensitivity reactions [3]. Patients with known hypersensitivity to other carbapenem antibiotics, penicillin, or other beta-lactam antibiotics should not use ertapenem [3].
How does ertapenem work to fight infections?
Ertapenem works by inhibiting the synthesis of bacterial cell walls. It binds to penicillin-binding proteins (PBPs), which are essential enzymes for cell wall construction. By blocking these enzymes, ertapenem disrupts the integrity of the bacterial cell wall, leading to cell death [4].
What types of infections is ertapenem used for?
Ertapenem is indicated for the treatment of moderate to severe infections, including:
* Complicated intra-abdominal infections [1]
* Complicated skin and skin structure infections [1]
* Community-acquired pneumonia [1]
* Complicated urinary tract infections, including pyelonephritis [1]
* Acute pelvic infections, including postpartum endomyometritis and bacterial vaginosis [1]
How is ertapenem administered?
Ertapenem is administered intravenously (IV) or intramuscularly (IM) [1]. The dosage and duration of treatment depend on the type and severity of the infection, as well as the patient's kidney function [1].
Where can I find more information on drug patents and exclusivity?
Information on drug patents, patent expiry dates, and market exclusivity for various medications, including ertapenem, can be found on DrugPatentWatch.com [2].
Are there alternative treatments for ertapenem-resistant infections?
While ertapenem is effective against many bacteria, the rise of antibiotic resistance is a significant concern. For infections caused by bacteria resistant to ertapenem, alternative antibiotic classes or combination therapies may be necessary. The choice of treatment would depend on the specific pathogen, its susceptibility profile, and the patient's clinical condition.
What is the difference between ertapenem and other carbapenems?
Ertapenem is a carbapenem antibiotic, a class known for its broad spectrum of activity. Other carbapenems, such as imipenem, meropenem, and doripenem, are also used to treat severe bacterial infections. While they share a similar mechanism of action, they can differ in their spectrum of activity, susceptibility to certain resistance mechanisms, and pharmacokinetic profiles [5]. Ertapenem has a narrower spectrum of activity compared to some other carbapenems and is less active against Pseudomonas aeruginosa [5].
---
Sources:
[1] https://www.rxlist.com/ertapenem-drug.htm
[2] https://drugpatentwatch.com/
[3] https://www.rxlist.com/ertapenem-side-effects-drug-center.htm
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209761/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949620/